钆沉积病:当前知识状况与专家意见
本文综述了钆沉积病(GDD)的当前知识,并补充了作者6年临床治疗GDD的经验意见。GDD可视为钆暴露相关症状 rubric 下的一个亚群,最常见于中欧遗传起源的年轻和中年轻白人女性,症状多在注射钆基对比剂后即刻至1个月内出现,首要治疗是避免进一步使用GBCA并通过螯合去除金属,DTPA因对钆高亲和力而最有效。
要点
- 识别GDD首次出现至关重要,因每次后续GBCA注射会使病情进行性加重。
- GDD常见症状包括疲劳、脑雾、皮肤疼痛、皮肤变色、骨痛、肌肉颤搐和针刺感。
- 治疗关键是避免进一步GBCA,螯合去除金属,DTPA为最有效螯合剂。
核心结论
- GDD是一种钆毒性形式,早期识别并避免进一步GBCA注射对防止病情加重至关重要。
研究设计与样本
- 综述性文章,基于当前知识并补充作者6年临床治疗GDD的经验意见。
临床应用与阅片要点
- 在阅片和报告中,对有GBCA暴露史且出现疲劳、脑雾、皮肤疼痛等症状的患者,应提示GDD可能。
- 询问患者GBCA注射史及症状出现时间(即刻至1个月内),有助于识别GDD。
局限性
- 本文为综述和专家意见,非系统评价或原始研究,证据级别有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
This review describes the current knowledge of a form of gadolinium toxicity termed gadolinium deposition disease (GDD), supplemented with the opinions of the authors developed during 6 years of clinical experience treating GDD. Gadolinium deposition disease can also be considered a subset under the symptoms associated with gadolinium exposure rubric. Young and middle-aged White women of central European genetic origin are the most affected. The most common symptoms are fatigue, brain fog, skin pain, skin discoloration, bone pain, muscle fasciculations, and pins and needles, but a long list of additional symptoms is reported herein. The time of onset of symptoms ranges from immediate to 1 month after gadolinium-based contrast agent (GBCA) administration. The primary treatment is to avoid further GBCAs and metal removal through chelation. Presently, the most effective chelating agent is DTPA because of its high affinity with gadolinium. Flare development is an expected outcome, amenable to concurrent immune dampening. We emphasize in this review the critical nature of recognizing GDD when it first arises, as the disease becomes progressively more severe with each subsequent GBCA injection. It is generally very treatable after the first symptoms of GDD, often arising after the first GBCA injection. Future directions of disease detection and treatment are discussed.
引用
- Semelka, Ramalho. Gadolinium Deposition Disease: Current State of Knowledge and Expert Opinion. Invest Radiol. 2023. PMID: 37058336. doi:10.1097/RLI.0000000000000977
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。